GlobeNewswire by notified

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

Share

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to coverPhase 3 development ofmavoglurant in cocaineuse disorder

Agreement follows STALICLA’srecent in-licencing of mavoglurant from Novartis

Geneva, Switzerland8March2023, STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). The agreement covers the clinical development program of mavoglurant to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

NIDA is the lead federal agency supporting scientific research on drug use and addiction to improve individual and public health. Under the terms of the CRADA, NIDA will cover under its own account the Phase 3 trial for mavoglurant, which is slated to enrol up to 330 patients. The investigational product was in-licensed by STALICLA from Novartis in return for undisclosed late-stage milestone payments and royalties, in an agreement announced in January this year. Novartis has also taken an equity stake in STALICLA.

Lynn Durham, STALICLA’s Founder & CEO, commented: “Our CRADA with NIDA allows us to enter into late stage development and is a testament to STALICLA’s commitment to bring new treatments to patients suffering from neuropsychiatric and neurodevelopmental disorders. It is also a validation of mavoglurant’s potential in treating patients with substance-abuse disorders. We have onboarded an exceptional partner in NIDA and we are excited about working together to accelerate mavoglurant towards a new drug application.”

About mavoglurant

Mavoglurant is the most clinically advanced selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist. mGluR5 has been tied to mood disorders, addiction as well as rare and common forms of Autism. In clinical Phase 2 studies, mavoglurant has been shown to induce abstinence in cocaine use disorder patients through inhibition of mGluR5, with no evidence of withdrawal liability.

About STALICLA

STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.

STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.

With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.

The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.

STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

Contacts

STALICLA SA
Lynn Durham, CEO
Lynn.durham@stalicla.com
Media enquiries
Consilium Strategic Communications
stalicla@consilium-comms.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

2023 var et godt år med opkøb og finansielle resultater som forventet29.2.2024 13:07:25 CET | pressemeddelelse

Selskabsmeddelelse nr. 2-2024 29. februar 2024 North Media koncernchef Lasse Brodt siger om udviklingen i 2023: ”Vi leverede et finansielt resultat i tråd med de senest udmeldte forventninger, hvilket var tilfredsstillende i lyset af, at flere af vores forretninger i løbet af året var påvirket af den økonomiske udvikling og usikre markedsforhold. FK Distribution oplevede, som forventet, et strukturelt fald i volumen, der påvirkede omsætningen, mens BoligPortal for første gang leverede en omsætning over 100 millioner kr. og det bedste driftsresultat nogensinde. Ofir og Bekey havde faldende omsætning og indtjening og vi har iværksat strategiske tiltag for at vende udviklingen. 2023 var også året, hvor vi eksekverede på vores strategi om at købe, drive og optimere volumenforretninger. Med købet af SDR Svensk Direktreklam AB, Sveriges største private distributør af tryksager og lokalaviser, udvider vi vores position i det skandinaviske marked.” Finansielle nøgletal: Mio. kr.4. kvartalHelår

2023 was a good year with acquisitions and financial results as guided29.2.2024 13:07:25 CET | Press release

Announcement no. 2-2024 29 February 2024 North Media’s Group CEO Lasse Brodt commented on the performance in 2023: “We’re delivering financial results in line with our most recent guidance, which we consider to be satisfactory in light of the fact that several of our businesses were still affected by the economic climate and the uncertain market conditions. FK Distribution reported a drop in volumes, as expected, which impacted our revenue, while BoligPortal delivered revenue of more than DKK 100 million for the first time ever and its best ever EBIT. Ofir and Bekey both reported declining revenue and earnings, and we have taken strategic steps to reverse that performance. This was also the year when we executed on our strategy to acquire, run and optimise high-volume businesses. By acquiring SDR Svensk Direktreklam AB, Sweden’s largest private-sector distributor of leaflets and local newspapers, we have expanded our Scandinavian position in that market.” Financial highlights: DKK mQ4F

Digital Science announces Catalyst Grant winners, supporting AI-based innovations to benefit research29.2.2024 13:00:00 CET | Press release

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Digital Science has awarded two new Catalyst Grants of £25,000 each to innovative AI-based technology ideas aimed at advancing global research. The winners will use the funding to develop their ideas, which include using AI to alleviate the burden on researchers of applying for research funding, and to predict research impact. The winning applications from Digital Science’s 2023 Catalyst Grant round announced today are: Atom – Tomer du Sautoy (co-founder and CEO) and Hamilton Evans (co-founder and CTO)Future Metric – Dr Amy Nelson (CEO) and Dr Mohamad Zeina (CTO) Atom – US-based (South Pasadena, California) Scientists Tomer du Sautoy and Hamilton Evans argue the current system of funding research is stifling scientific discovery, with the world’s leading researchers spending up to 50% of their time on grant applications instead of on science. They aim to build an “end-to-end system” using neural matching, Generative AI and automated workflows “

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights29.2.2024 13:00:00 CET | Press release

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights:COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025Teri Loxam to assume Chief Financial Officer role on March 1, 2024Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024Conference call February 29 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, “We continue to progress our two phase 3 trials of COMP360 in treatment-resistant depression with top-line data expected this year and next. While our overall Phase 3 trial completion remains on track with the

Fujifilm Healthcare Europe partners with R Zero to bring next-gen training simulation technology to European endoscopists29.2.2024 12:36:48 CET | Press release

RATINGEN, Germany, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fujifilm Healthcare Europe GmbH has announced a strategic partnership with R Zero for the exclusive distribution of mikoto, a state-of-the-art endoscopy simulation technology, throughout Europe. This collaboration aims at providing training solutions for endoscopy professionals across the region, to enhance their skills with the intention to improve patient outcomes. As a first step in this partnership, Fujifilm Healthcare Europe will introduce the mikoto colon model to the European market. This advanced and portable medical training simulator enables self-learning by evaluating and scoring procedures using various sensors combined with Artificial intelligence offering four levels of difficulty. In addition to the mikoto colon model, R Zero is currently developing other endoscopic simulators, including upper GI, ERCP, ESD and EMR. These upcoming simulation technologies will provide further training options for endoscopists, allowing

HiddenA line styled icon from Orion Icon Library.Eye